Kineret

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

anakinra

Available from:

Swedish Orphan Biovitrum AB (publ)

ATC code:

L04AC03

INN (International Name):

anakinra

Therapeutic group:

imunosupresivi

Therapeutic area:

Arthritis, Rheumatoid; COVID-19 virus infection

Therapeutic indications:

Reumatoidni artritis (RA)Kinneret prikazan kod odraslih za liječenje znakova i simptoma RA u kombinaciji s metotreksatom, sa neadekvatno odgovorom na metotreksat samo . COVID-19Kineret is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) ≥ 6 ng/ml. Periodična groznica syndromesKineret je indiciran za liječenje sljedećih аутовоспалительные sindromi periodična bolest kod odraslih, mlade, djecu i dojenčad u dobi od 8 mjeseci i stariji s tjelesnu masu od 10 kg i gore:криопиринассоциированные periodične sindromi (CAPS)s Kinneret indiciran za liječenje poklopaca, uključujući:za novorođenčad-početak Мультисистемное upalna bolest (НОМИД) / kronični инфантильный neurološki, kožni, zglobne sindrom (Синка)Макла-Wells sindrom (Mw)obiteljska холодовая Аутовоспалительные sindrom (FCAS)obiteljska mediteranska groznica (ФМФ)Kinneret indiciran za liječenje obiteljska mediteranska groznica (ФМФ). Kinneret mora se dati u kombinaciji s drugim lijekovima, ako je potrebno. Još DiseaseKineret navodi u odrasle, mlade, djecu i dojenčad u dobi od 8 mjeseci i stariji s tjelesnu masu od 10 kg i gore za liječenje bolesti Стилла-Шоффара, uključujući i sistem juvenilni idiopatski artritis (SJIA) i odrasloj dobi bolest Стилла-Шоффара (AOP), s aktivnim sistemske funkcije umjerena do visoka aktivnost bolesti, ili kod pacijenata s trajna aktivnost bolesti nakon liječenja nesteroidni protuupalni lijekovi (NSAR) i glukokortikoidi. Kinneret može se dati u monoterapiji ili u kombinaciji s drugim anti-upalne lijekove i заболевани-razrađen antirheumatic napitke (dmards).

Product summary:

Revision: 34

Authorization status:

odobren

Authorization date:

2002-03-08

Patient Information leaflet

                                30
B. UPUTA O LIJEKU
31
UPUTA O LIJEKU: INFORMACIJE ZA KORISNIKA
KINERET 100 MG/0,67 ML OTOPINA ZA INJEKCIJU U NAPUNJENOJ ŠTRCALJKI
anakinra
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO POČNETE PRIMJENJIVATI
OVAJ LIJEK JER SADRŽI VAMA
VAŽNE PODATKE.
-
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
-
Ako imate dodatnih pitanja, obratite se liječniku ili ljekarniku.
-
Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im
naškoditi, čak i ako su
njihovi znakovi bolesti jednaki Vašima.
-
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika ili ljekarnika. To
uključuje i svaku moguću nuspojavu koja nije navedena u ovoj uputi.
Pogledajte dio 4.
ŠTO SE NALAZI U OVOJ UPUTI:
1.
Što je Kineret i za što se koristi
2.
Što morate znati prije nego počnete primjenjivati Kineret
3.
Kako primjenjivati Kineret
4.
Moguće nuspojave
5.
Kako čuvati Kineret
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE KINERET I ZA ŠTO SE KORISTI
Kineret sadrži djelatnu tvar anakinra. To je vrsta citokina
(imunosupresivna tvar) koja se koristi za
liječenje:
-
reumatoidnog artritisa (RA)
-
bolesti COVID-19 u bolesnika koji imaju upalu pluća, trebaju dodatni
kisik i u kojih postoji
rizik od zatajenja pluća
-
sindroma periodičnih vrućica:
-
periodičnih sindroma povezanih s kriopirinom (engl.
_Cryopyrin-Associated Periodic _
_Syndromes_, CAPS):
o
neonatalne multisistemske upalne bolesti (engl. _Neonatal-Onset
Multisystem _
_Inflammatory Disease_, NOMID) ili takozvanog kroničnog infantilnog
neurološkog,
kutanog i zglobnog sindroma (engl. _Chronic Infantile Neurological,
Cutaneous, _
_Articular Syndrome_, CINCA)
o
Muckle-Wellsovog sindroma (MWS)
o
obiteljskog autoupalnog sindroma uzrokovanog hladnoćom (engl.
_Familial Cold _
_Autoinflammatory Syndrome_, FCAS)
-
obiteljske mediteranske groznice (engl. _Familial Mediterranean
Fever_, FMF)
-
Stillove bolesti, uključujući sistemski juvenilni idiopatski
artritis (SJIA) i Stillovu bolest odrasle
dobi (engl. _Adult-Onset St
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
Kineret 100 mg/0,67 ml otopina za injekciju u napunjenoj štrcaljki
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Jedna kalibrirana napunjena štrcaljka sadrži 100 mg anakinre* u 0,67
ml (150 mg/ml).
* Antagonist receptora humanog interleukina-1 (r-metHuIL-1ra)
proizveden na stanicama _Escherichia _
_coli_ tehnologijom rekombinantne DNA.
Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Otopina za injekciju (injekcija).
Bistra, bezbojna do bijela otopina za injekciju koja može sadržavati
neke prozirne do bijele amorfne
čestice porijeklom od lijeka.
4.
KLINIČKI PODACI
4.1
TERAPIJSKE INDIKACIJE
Reumatoidni artritis (RA)
Kineret je indiciran u odraslih za liječenje znakova i simptoma RA u
kombinaciji s metotreksatom, u
osoba s neodgovarajućim odgovorom na sam metotreksat.
COVID-19
Kineret je indiciran za liječenje koronavirusne bolesti 2019
(COVID-19) u odraslih bolesnika s
pneumonijom kojima je potrebna nadomjesna terapija kisikom (niskim ili
visokim protokom kisika) i
u kojih postoji rizik od progresije do teškog zatajenja disanja
definiranog koncentracijom topljivog
receptora za urokinazni tip aktivatora plazminogena (engl. _soluble
urokinase plasminogen activator _
_receptor,_ suPAR) u plazmi ≥ 6 ng/ml (vidjeti dijelove 4.2, 4.4 i
5.1).
Sindromi periodičnih vrućica
Kineret je indiciran za liječenje sljedećih autoupalnih sindroma
periodičnih vrućica u odraslih,
adolescenata, djece i dojenčadi u dobi od 8 mjeseci i starije s
tjelesnom težinom od najmanje 10 kg ili
više:
_Periodični sindromi povezani s kriopirinom_ (_engl.
Cryopyrin-Associated Periodic Syndromes, CAPS) _
Kineret je indiciran za liječenje CAPS-a, uključujući:
-
neonatalnu multisistemsku upalnu bolest (engl. _Neonatal-Onset
Multisystem Inflammatory _
_Disease, _NOMID) / kronični infantilni neurološki, kutani i zglobni
sindrom (engl. _Chronic _
_Infantile Neurological, Cutaneous, Articular Syndrome_, CINCA)
-
Muckle-Wellsov sindrom (MWS)
-
obiteljs
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 21-03-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 21-03-2024
Public Assessment Report Public Assessment Report Bulgarian 22-12-2021
Patient Information leaflet Patient Information leaflet Spanish 21-03-2024
Public Assessment Report Public Assessment Report Spanish 22-12-2021
Patient Information leaflet Patient Information leaflet Czech 21-03-2024
Public Assessment Report Public Assessment Report Czech 22-12-2021
Patient Information leaflet Patient Information leaflet Danish 21-03-2024
Public Assessment Report Public Assessment Report Danish 22-12-2021
Patient Information leaflet Patient Information leaflet German 21-03-2024
Public Assessment Report Public Assessment Report German 22-12-2021
Patient Information leaflet Patient Information leaflet Estonian 21-03-2024
Public Assessment Report Public Assessment Report Estonian 22-12-2021
Patient Information leaflet Patient Information leaflet Greek 21-03-2024
Public Assessment Report Public Assessment Report Greek 22-12-2021
Patient Information leaflet Patient Information leaflet English 21-03-2024
Public Assessment Report Public Assessment Report English 22-12-2021
Patient Information leaflet Patient Information leaflet French 21-03-2024
Public Assessment Report Public Assessment Report French 22-12-2021
Patient Information leaflet Patient Information leaflet Italian 21-03-2024
Public Assessment Report Public Assessment Report Italian 22-12-2021
Patient Information leaflet Patient Information leaflet Latvian 21-03-2024
Public Assessment Report Public Assessment Report Latvian 22-12-2021
Patient Information leaflet Patient Information leaflet Lithuanian 21-03-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 21-03-2024
Public Assessment Report Public Assessment Report Lithuanian 22-12-2021
Patient Information leaflet Patient Information leaflet Hungarian 21-03-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 21-03-2024
Public Assessment Report Public Assessment Report Hungarian 22-12-2021
Patient Information leaflet Patient Information leaflet Maltese 21-03-2024
Public Assessment Report Public Assessment Report Maltese 22-12-2021
Patient Information leaflet Patient Information leaflet Dutch 21-03-2024
Public Assessment Report Public Assessment Report Dutch 22-12-2021
Patient Information leaflet Patient Information leaflet Polish 21-03-2024
Public Assessment Report Public Assessment Report Polish 22-12-2021
Patient Information leaflet Patient Information leaflet Portuguese 21-03-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 21-03-2024
Public Assessment Report Public Assessment Report Portuguese 22-12-2021
Patient Information leaflet Patient Information leaflet Romanian 21-03-2024
Public Assessment Report Public Assessment Report Romanian 22-12-2021
Patient Information leaflet Patient Information leaflet Slovak 21-03-2024
Public Assessment Report Public Assessment Report Slovak 22-12-2021
Patient Information leaflet Patient Information leaflet Slovenian 21-03-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 21-03-2024
Public Assessment Report Public Assessment Report Slovenian 22-12-2021
Patient Information leaflet Patient Information leaflet Finnish 21-03-2024
Public Assessment Report Public Assessment Report Finnish 22-12-2021
Patient Information leaflet Patient Information leaflet Swedish 21-03-2024
Public Assessment Report Public Assessment Report Swedish 22-12-2021
Patient Information leaflet Patient Information leaflet Norwegian 21-03-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 21-03-2024
Patient Information leaflet Patient Information leaflet Icelandic 21-03-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 21-03-2024

Search alerts related to this product

View documents history